AZN.LN: MYSTICal Endpoints unravelled

Endpoints claified: There have recently been some uncertainties surrounding the exact endpoint and timings of the upcoming MYSTIC IO/IO combination study of Astra’s PD-L1 durvalumab with their CTLA4 tremelimumab in 1st line lung cancer. In-line with our thesis in Foveal’s note of 5th December, AstraZeneca confirmed that MYSTIC will assess OS and PFS will be endpoints for PD-L1 expressing patients. We have long argued that MYSTIC will likely ...

Login in to download pdf